23 Jul, 2026
According to Straits Research, the global vagus nerve stimulation market size was valued at $575.81 million in 2025 and is projected to reach $974.30 million by 2034, at a CAGR of 6.06% during the forecast period 2026–2034.
The growth of the global vagus nerve stimulation market is primarily driven by the rising prevalence of neurological disorders, including epilepsy and other chronic conditions, which is increasing the demand for effective treatment options. Healthcare professionals are actively promoting neurostimulation therapies such as VNS to achieve better clinical outcomes. Moreover, rising investments in research and development and collaborations between medical device manufacturers and healthcare institutions are accelerating innovation in neurostimulation technologies.
However, the market faces restraints such as the high cost of VNS devices and procedures, which limit patient accessibility, particularly in low and middle-income regions. Additionally, stringent regulatory requirements for approval and reimbursement pose challenges for market entry and expansion.
On the other hand, expanding VNS applications into emerging indications and novel patient populations presents substantial untapped potential. Increasing clinical trials exploring VNS for conditions such as chronic pain and inflammatory diseases are opening new avenues for market growth. Furthermore, growing awareness among physicians and patients regarding non-pharmacological treatment options is likely to strengthen adoption and support long-term market expansion.
North America dominated the vagus nerve stimulation market in 2025, accounting for 54.78% market share. This dominance is attributed to the presence of major players such as LivaNova, electroCore, and MicroTransponder having strong regional operations. Their local R&D centers, faster FDA approvals, and extensive distribution networks ensure quicker access to advanced implantable and non-invasive VNS therapies.
Asia Pacific is emerging as the fastest growing region with a CAGR of 8.21% from 2026 to 2034, owing to the rising prevalence of neurological disorders such as epilepsy, Alzheimer’s disease, and stroke-related complications. Rapid urbanization, changing lifestyles, and increasing stress levels have contributed to higher incidences of these conditions. The growing disease burden is driving demand for effective neuromodulation therapies like vagus nerve stimulation across the region.
sales@straitsresearch.com